Department of Dermatology, Kanto Central Hospital, Tokyo, Japan.
Department of Pediatrics, Kanto Central Hospital, Tokyo, Japan.
J Dermatol. 2018 Sep;45(9):1109-1112. doi: 10.1111/1346-8138.14517. Epub 2018 Jun 28.
Infantile hemangiomas are the most common tumor of childhood and undergo rapid growth during early infancy followed by gradual involution. After involution, residual lesions sometimes remain. Oral propranolol usually induces earlier involution and redness reduction of infantile hemangiomas. However, the optimal treatment duration is unknown and infantile hemangiomas sometimes recur after cessation of treatment. We report three Japanese patients with recurrent infantile hemangiomas on their cheek. These patients were a 1-month-old female baby with a superficial infantile hemangioma, a 3-month-old female baby with a mixed infantile hemangioma and a 4-month-old male baby with a mixed infantile hemangioma. Two of them also received pulsed dye laser treatment. They did not reach complete or nearly complete resolution of infantile hemangiomas at week 25. These patients experienced regrowth of their infantile hemangioma after 20 months of age and took propranolol after the age of 24 months. There were no severe adverse effects. Propranolol may not only be therapeutic but also prophylactic. Patients with infantile hemangiomas who have taken oral propranolol should be followed up at least 6 months after cessation of treatment, especially infantile hemangiomas on the cheek, and those with partial response to propranolol may require close attention in prolonged growth.
婴幼儿血管瘤是儿童中最常见的肿瘤,在婴儿早期经历快速生长,随后逐渐消退。消退后,残余病变有时仍然存在。口腔普萘洛尔通常会诱导婴幼儿血管瘤更早地消退和红色减少。然而,最佳治疗持续时间尚不清楚,并且婴幼儿血管瘤在停止治疗后有时会复发。我们报告了三名颊部复发性婴幼儿血管瘤的日本患者。这些患者包括一名 1 个月大的女性婴儿,患有浅表性婴幼儿血管瘤;一名 3 个月大的女性婴儿,患有混合性婴幼儿血管瘤;以及一名 4 个月大的男性婴儿,患有混合性婴幼儿血管瘤。其中两名患者还接受了脉冲染料激光治疗。他们在第 25 周时未达到婴幼儿血管瘤完全或接近完全消退。这些患者在 24 个月大后经历了婴幼儿血管瘤的复发,并在 24 个月大后服用了普萘洛尔。没有严重的不良反应。普萘洛尔不仅具有治疗作用,而且具有预防作用。服用口服普萘洛尔的婴幼儿血管瘤患者在停止治疗后至少应随访 6 个月,特别是颊部的婴幼儿血管瘤,对于那些对普萘洛尔部分反应的患者,在长时间生长过程中可能需要密切关注。